Trodelvy (sacituzumab govitecan) 200mg Injection In Pakistan

Trodelvy 200 mg Injection contains sacituzumab govitecan, an antibody-drug conjugate used in the treatment of certain types of cancer. It is a targeted anticancer medicine that delivers a cancer-killing agent to cells expressing the Trop-2 protein.

Trodelvy is administered intravenously by qualified healthcare professionals under the supervision of an oncologist. It is generally supplied as a powder that must be reconstituted before infusion.

Uses of Trodelvy Injection

Trodelvy may be prescribed for eligible adults with the following conditions:

• Triple-negative breast cancer (TNBC): Unresectable locally advanced or metastatic disease, depending on previous treatment and eligibility.

• HR-positive, HER2-negative breast cancer: Advanced or metastatic disease that has progressed after specified previous treatments.

   

Product Information

Important strength note: The current US prescribing information lists Trodelvy as a 180 mg single-dose vial, while 200 mg presentations are listed in some other markets. Confirm the exact strength and packaging with the supplier before ordering.

Before purchasing, confirm the product's authenticity, batch number, expiry date, required refrigerated storage, and import documentation with a licensed oncology medicine supplier.

Side Effects and Precautions

Possible side effects include:

• Low white blood cell counts and increased risk of infection

• Diarrhea

• Nausea and vomiting

• Fatigue

• Hair loss

• Infusion-related or allergic reactions

Severe neutropenia and diarrhea are important warnings. Patients require blood-count monitoring and medical supervision throughout treatment.